# MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

> **NCT02575339** · PHASE1,PHASE2 · TERMINATED · sponsor: **Kathy Miller** · enrollment: 11 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer
- HCC

## Interventions

- **DRUG:** MLN0128
- **DRUG:** MLN0128 (RP2D)
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02575339
- **Lead sponsor:** Kathy Miller
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-18
- **Primary completion:** 2018-06-26
- **Final completion:** 2020-11-24
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Funder Decision
- **Last updated:** 2022-07-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02575339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02575339, "MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02575339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*